

WRITER'S DIRECT DIAL:  
(800) 886-5833


October 18, 2005

Temp. Ref.: 3999.002383

CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 18, 2005  
Date

  
Shelley P.M. Fussey

MAILSTOP ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RE: *U.S. Application Serial No. 09/351,149; Entitled "Cancer Treatment Kits Comprising Therapeutic Conjugates That Bind To Aminophospholipids"; Thorpe, Ran and Brekken; U.T. Ref.: UTSD:0556--2 US; Peregrine Family: UTS5; Our Temp. Ref.: 3999.002383*

Sir:

Enclosed for filing in the above-referenced patent application are:

- 1) An Issue Fee Transmittal; **please deduct the large entity issue fee and the advance order patent copy fees from Applicants' representatives' deposit account, Peregrine Pharmaceuticals, Inc., P.C. Deposit Account No. 50-3493/3999.002383;**
- 2) Amendment Under 37 C.F.R. § 1.312, Comments on Statement of Reasons for Allowance and Applicants' Interview Summaries;
- 3) Revocation of Power of Attorney; Election Under 37 C.F.R. §§ 3.71 and 3.73 and New Power of Attorney; and Change of Correspondence Address; and
- 4) A postcard listing these materials.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 to 1.21 that may be required for any reason relating to these documents, or credit any overpayment to Peregrine Pharmaceuticals, Inc., P.C. Deposit Account No. 50-3493/3999.002383.

October 18, 2005

Page 2

Please date stamp and return the postcard evidencing receipt of these materials

Respectfully submitted  
PEREGRINE PHARMACEUTICALS, INC.  
CUSTOMER NO. 000052101



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

Encl.